NVAMD

(redirected from Neovascular Age-Related Macular Degeneration)
AcronymDefinition
NVAMDNeovascular Age-Related Macular Degeneration (ophthalmology)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Aerie Pharmaceuticals announced the commencement of patient dosing in a first-in-human clinical trial of AR-13503 Sustained Release, or SR, Implant in patients with neovascular age-related macular degeneration, or nAMD, or diabetic macular edema, or DME.
Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Which of the following is NOT an anti-VEGF used to treat advanced neovascular age-related macular degeneration?
Novartis AG (VTX: NOVN) has released new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (nAMD) from a pre-specified secondary analysis of the Phase III HAWK and HARRIER trials, the company disclosed on Tuesday.
They look at OCT angiography in relation to the basics, artifacts, clinical systems, neovascular age-related macular degeneration, fibrotic choroidal neovascularization in age-related macular degeneration, non-neovascular age-related macular degeneration, diabetic retinopathy, arterial occlusions, retinal venous occlusions, central serious chorioretinopathy, macular telangiectasia type two, adult-onset foveomacular vitelliform dystrophy, high myopia, uveitis, ocular oncology and radiation retinopathy, glaucoma, anterior segment vasculature, and the future.
Our experience was consistent with that of published case series, which showed intravitreal antivascular endothelial growth factors (VEGF) injections to be effective for POHS related CNV; on average, patients' visual acuity improved requiring relatively few treatments (range 2.6 to 7 injections per patient per year) [1-4] as compared to neovascular age-related macular degeneration (AMD).
Daien et al., "Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors," Progress in Retinal and Eye Research, vol.
The use of community-based referral refinement schemes by optometrists have been proven to work well for conditions such as glaucoma, and recent research has found that optometry based community care for routine monitoring of neovascular age-related macular degeneration can be just as effective as hospital-based care (Echoes trial).
[53] Eye Disease Case-Control Study Group, "Antioxidant status and neovascular age-related macular degeneration. Eye Disease Case-Control Study Group," Archives of Ophthalmology, vol.
Contrary to what was argued by some experts the review has found that the cheaper drug, bevacizumab, does not appear to increase deaths or serious side-effects compared with ranibizumab in people with neovascular age-related macular degeneration.